Sarcopenia – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Sarcopenia – Pipeline Review, H1 2020’, provides an overview of the Sarcopenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sarcopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Sarcopenia

– The report reviews pipeline therapeutics for Sarcopenia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Sarcopenia therapeutics and enlists all their major and minor projects

– The report assesses Sarcopenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Sarcopenia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Sarcopenia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Sarcopenia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AAVogen Inc

Armgo Pharma Inc

Biophytis SA

Elevian Inc

Faraday Pharmaceuticals Inc

Gerologix Inc

Helixmith Co Ltd

Immusoft Corp

Keren Therapeutics

MYOS RENS Technology Inc

Neurotune AG

Oncocross Co Ltd

OPKO Health Inc

PhaseBio Pharmaceuticals Inc

Rejuvenate Biomed NV

Ridgeline Therapeutics LLC

ST Pharm Co Ltd

Teijin Pharma Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sarcopenia - Overview

Sarcopenia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Sarcopenia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sarcopenia - Companies Involved in Therapeutics Development

AAVogen Inc

Armgo Pharma Inc

Biophytis SA

Elevian Inc

Faraday Pharmaceuticals Inc

Gerologix Inc

Helixmith Co Ltd

Immusoft Corp

Keren Therapeutics

MYOS RENS Technology Inc

Neurotune AG

Oncocross Co Ltd

OPKO Health Inc

PhaseBio Pharmaceuticals Inc

Rejuvenate Biomed NV

Ridgeline Therapeutics LLC

ST Pharm Co Ltd

Teijin Pharma Ltd

Sarcopenia - Drug Profiles

ARM-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVGN-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sarcopenia - Dormant Projects

Sarcopenia - Discontinued Products

Sarcopenia - Product Development Milestones

Featured News & Press Releases

Appendix

List of Tables

List of Tables

Number of Products under Development for Sarcopenia, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Sarcopenia – Pipeline by AAVogen Inc, H1 2020

Sarcopenia – Pipeline by Armgo Pharma Inc, H1 2020

Sarcopenia – Pipeline by Biophytis SA, H1 2020

Sarcopenia – Pipeline by Elevian Inc, H1 2020

Sarcopenia – Pipeline by Faraday Pharmaceuticals Inc, H1 2020

Sarcopenia – Pipeline by Gerologix Inc, H1 2020

Sarcopenia – Pipeline by Helixmith Co Ltd, H1 2020

Sarcopenia – Pipeline by Immusoft Corp, H1 2020

Sarcopenia – Pipeline by Keren Therapeutics, H1 2020

Sarcopenia – Pipeline by MYOS RENS Technology Inc, H1 2020

Sarcopenia – Pipeline by Neurotune AG, H1 2020

Sarcopenia – Pipeline by Oncocross Co Ltd, H1 2020

Sarcopenia – Pipeline by OPKO Health Inc, H1 2020

Sarcopenia – Pipeline by PhaseBio Pharmaceuticals Inc, H1 2020

Sarcopenia – Pipeline by Rejuvenate Biomed NV, H1 2020

Sarcopenia – Pipeline by Ridgeline Therapeutics LLC, H1 2020

Sarcopenia – Pipeline by ST Pharm Co Ltd, H1 2020

Sarcopenia – Pipeline by Teijin Pharma Ltd, H1 2020

Sarcopenia – Dormant Projects, H1 2020

Sarcopenia – Dormant Projects, H1 2020 (Contd..1), H1 2020

Sarcopenia – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Sarcopenia, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports